Status:
COMPLETED
Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit
Lead Sponsor:
QIAGEN Gaithersburg, Inc
Collaborating Sponsors:
Amgen
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
Brief Summary
A Non-interventional Biomarker Study for the testing of DNA extracted from tumour tissue biopsy samples, using the therascreen® KRAS RGQ PCR Kit, from patients with Non-Small Cell Lung Cancer, screene...
Detailed Description
This is a non-interventional, biomarker screening clinical performance study protocol, for the testing of DNA extracted from tumour tissue biopsy samples (resected and core needle biopsy \[CNB\]/fine ...
Eligibility Criteria
Inclusion
- All patients who provided consent (by signing and dating the ICF for Protocol No.
- 20190294), may be included in the Clinical Performance Study.
Exclusion
- Patients whose tumour tissue biopsy samples that are not Clinical Study Assay evaluable
- Patients with samples identified for the study which have insufficient testing material
- Specimens which have undergone decalcification.
Key Trial Info
Start Date :
April 2 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 26 2022
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT05360225
Start Date
April 2 2020
End Date
May 26 2022
Last Update
November 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QIAGEN Gaithersburg, Inc
Manchester, United Kingdom, M130BH